Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Allogene Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic chimeric antigen receptor T cell (CAR T) therapies for the treatment of cancer. The company operates within the biotechnology and oncology therapeutics industries, with a core emphasis on “off-the-shelf” cell therapies designed to overcome the manufacturing, cost, and scalability limitations of autologous CAR T treatments. Its primary revenue drivers are currently research and development activities, supported by equity financing and collaboration-related payments, as the company does not yet have approved commercial products.
Allogene’s strategy centers on creating readily available CAR T therapies for large patient populations, primarily in hematologic malignancies. The company was founded in 2018 by former leaders of Kite Pharma, including David Chang, following Kite’s acquisition by Gilead Sciences. At inception, Allogene acquired a portfolio of allogeneic CAR T assets and related intellectual property from Pfizer Inc., which formed the foundation of its current pipeline and platform.
Business Operations
Allogene operates as a single reportable segment focused on the discovery, development, and potential commercialization of allogeneic CAR T therapies. Its core assets include proprietary gene-editing and T-cell engineering technologies designed to enable donor-derived CAR T cells with reduced risk of graft-versus-host disease and enhanced persistence. The company’s clinical pipeline includes product candidates such as ALLO-501, ALLO-501A, and ALLO-715, primarily targeting B-cell malignancies and multiple myeloma.
Operations are primarily based in the United States, with research, clinical development, and corporate functions integrated under centralized management. Allogene relies on a combination of internal capabilities and third-party manufacturers for clinical trial material production. The company maintains strategic collaborations, including development and regional partnerships, and holds interests in joint ventures intended to support international development. Data inconclusive based on available public sources regarding the extent of commercialization-related infrastructure beyond clinical-stage activities.
Strategic Position & Investments
Allogene’s strategic direction emphasizes advancing its clinical pipeline toward later-stage trials while refining its allogeneic CAR T platform to improve safety, durability, and manufacturing efficiency. Growth initiatives include expanding indications for existing candidates, developing next-generation constructs, and leveraging gene-editing technologies to broaden applicability across oncology indications. The company has made substantial investments in clinical trials and process development rather than diversification into non-core therapeutic areas.
A notable strategic investment is Allogene’s participation in Allogene Overland, a joint venture with a China-based biotechnology partner, established to develop and commercialize certain allogeneic CAR T products in China. Allogene has also entered into research and development collaborations with international pharmaceutical partners to extend the geographic reach of its programs. The company remains focused on oncology, with no verified public evidence of expansion into non-oncology therapeutic sectors.
Geographic Footprint
Allogene Therapeutics is headquartered in South San Francisco, California, within the United States, and conducts the majority of its operations domestically. Its U.S. presence includes corporate offices, research and development activities, and clinical trial oversight. Clinical studies are conducted across multiple sites, primarily in North America, with select international trial locations depending on regulatory approvals and partnerships.
Internationally, Allogene’s footprint is largely strategic rather than operational, centered on collaborations and joint ventures. Through Allogene Overland, the company has an investment presence in Asia, specifically China, aimed at supporting regional development and potential commercialization. Beyond these initiatives, data inconclusive based on available public sources regarding significant standalone operational facilities outside the United States.
Leadership & Governance
Allogene was co-founded by executives with prior leadership experience at Kite Pharma, shaping a governance approach focused on scientific rigor, disciplined capital allocation, and long-term value creation in cell therapy. The leadership team emphasizes platform scalability, clinical differentiation, and operational execution as core elements of its strategic vision.
Key executives include:
- David Chang – President and Chief Executive Officer
- Garry C. McGonigle – Chief Financial Officer
- Rahul R. Aggarwal, M.D. – Chief Medical Officer
- Alan Korman, Ph.D. – Chief Scientific Officer
- Elizabeth A. Czerepak – Chief Operating Officer
The board and executive leadership collectively guide corporate strategy, risk management, and governance, with experience spanning biotechnology R&D, large pharmaceutical operations, and public company leadership.